Skip to main content
SpringerLink
Log in

Cholinergic Adverse Effects of Cholinesterase Inhibitors in Alzheimer’s Disease

Epidemiology and Management

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Cholinergic adverse effects of acetylcholinesterase inhibitors (AChEIs) are caused by their central and peripheral pharmacological actions on a variety of organ tissues. Gastrointestinal adverse effects predominate and these were relatively common in the phase II and III randomised clinical trials of AChEIs for the treatment of probable Alzheimer’s disease. However, in these studies forced and rapid titration of drugs was used, which is not the case in clinical practice. Although there is a risk of pharmacodynamic interactions with other drugs leading to enhanced cholinergic adverse effects, very few of these interactions have proven to be clinically significant. Unresolved issues include the mechanism of syncope and neuromuscular weakness, which should be resolved through structured pharmacovigilance programmes and clinical studies. Loss of bodyweight may prove to be a long term significant complication. As a class, the AChEIs have proven to be well tolerated in the symptomatic treatment of Alzheimer’s disease in its mild-to-moderately severe stages. The incidence and clinical significance of cholinergic adverse events will need to be carefully studied if the drugs are used for indications other than Alzheimer’s disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III
Table IV
Table V
Table VI
Table VII
Table VIII
Table IX
Table X

Similar content being viewed by others

References

  1. Ormrod D, Spencer C. Metrifonate: a review of its use in Alzheimer’s disease. CNS Drugs 2000; Jun 13(6): 443–67

    Article  CAS  Google Scholar 

  2. Giacobini E. Cholinesterase inhibitors for Alzheimer’s disease therapy: from tacrine to future applications. Neurochem Int 1998; 32: 413–9

    Article  PubMed  CAS  Google Scholar 

  3. Pepeu G. Preclinical pharmacology of cholinesterase inhibitors. In: Giacobini E, editor. Cholinesterases and cholinesterase inhibitors. London: Martin Dunitz Publisher, 2000: 145–55

    Google Scholar 

  4. Giacobini E. Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy. Giacobini E, editor. Cholinesterases and cholinesterase inhibitors. London: Martin Dunitz Publisher, 2000: 181–226

    Google Scholar 

  5. Doody RS, Geldmacher DS, Pratt RD, et al. Optimal donepezil efficacy in Alzheimer’s disease is dependant on continued administration. Presented at the 9th Meeting of the European Neurological Society; 1999 Jun 5–9; Milan.

  6. Friedman JH. ’Drug holiday’ in the treatment of Parkinson’s disease: a brief review. Arch Intern Med 1985; 145: 913–5

    Article  PubMed  CAS  Google Scholar 

  7. Gauthier S. Acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease. Exp Opin Invest Drugs 1999; 8: 1511–20

    Article  CAS  Google Scholar 

  8. Nordberg A, Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer’s disease. Drug Saf 1998; Dec 19(6): 465–80

    Article  PubMed  CAS  Google Scholar 

  9. Crimson ML. Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer’s disease. Pharmacotherapy 1998; 18: 47–54

    Google Scholar 

  10. Schachter AS, Davis KL. Guidelines for the appropriate use of cholinesterase inhibitors in patients with Alzheimer’s disease. CNS Drugs 2000; Apr 11(4): 281–8

    Article  Google Scholar 

  11. Samuels SC. Alzheimer disease treatment: a focus on cholinesterase inhibitors. Primary Psychiatry 2000; 7: 62–6

    Google Scholar 

  12. VanDenBerg CM, Kazmi Y, Jann MW. Cholinesterase inhibitors for the treatment of Alzheimer’s disease in the elderly. Drugs Aging 2000; Feb 16(2): 123–38

    Article  PubMed  CAS  Google Scholar 

  13. Folstein MF, Folstein SE, McHugh PR. Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98

    Article  PubMed  CAS  Google Scholar 

  14. Cutler NR, Sramek JJ. Tolerability profiles of AchEIs: a critical component of care for Alzheimer’s disease patients. Int J Geriatr Psychopharmacol 1998; 1Suppl. 1: S20–5

    CAS  Google Scholar 

  15. Corey-Bloom J, Anand R, Veach J, for the ENA713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild-to-moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998; 1: 55–65

    CAS  Google Scholar 

  16. Rösier M, Anand R, Cicin-Sain A, et al., on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: results of an international, 26-week, multicentre, randomised, placebo-controlled trial. BMJ 1999; 318: 633–8

    Google Scholar 

  17. Cummings JL, Cyrus PA, Bieber F, et al. Metrifonate treatment of the cognitive deficits of Alzheimer’s disease. Neurology 1998; 50: 1214–21

    Article  PubMed  CAS  Google Scholar 

  18. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral and global function in patients with Alzheimer’s disease. Neurology 1998; 50: 1222–30

    Article  PubMed  CAS  Google Scholar 

  19. Dubois B, McKeith I, Orgogozo JM, et al. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer’s disease: the MALT study. Int J Geriatr Psychiatry 1999; 14: 973–82

    Article  PubMed  CAS  Google Scholar 

  20. Rogers SL, Friedhoff T, and the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7: 293–303

    PubMed  CAS  Google Scholar 

  21. Rogers SL, Doody R, Mohs RC, Donepezil Study Group, et al. Donepezil improves cognition and global function in Alzheimer disease. Arch Intern Med 1998; 158: 1021–31

    Article  PubMed  CAS  Google Scholar 

  22. Rogers SL, Farlow MR, Doody RS, Donepezil Study Group, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998; 50: 136–45

    Article  PubMed  CAS  Google Scholar 

  23. Burns A, Rossor M, Hecker J, Donepezil Study Group, et al. Donepezil in the treatment of Alzheimer’s disease: results from a multinational clinical trial. Dement Geriatr Cogn Disord 1999; 10: 237-44

  24. Tariot PN, Solomon PR, Morris JC, Galantamine USA-10 Study Group, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 2269–76

    Article  PubMed  CAS  Google Scholar 

  25. Raskind MA, Peskind ER, Wessel T, Galantamine USA-1 Study Group, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261–8

    Article  PubMed  CAS  Google Scholar 

  26. Wilcock GK, Lilienfeld S, Gaens E, on behalf of the Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer’s disease: multicentre randomised controlled trial. BMJ 2000; 321: 1–7

    Article  Google Scholar 

  27. Cutler NR, Anand R, Hartman RD, et al. Antiemetic therapy for Alzheimer’s patients receiving the cholinesterase inhibitor SDZ ENA 713 [abstract]. Clin Pharmacol Ther 1998; 63: 188

    Google Scholar 

  28. Medina A, Bodick N, Goldberger A, et al. Effects of central muscarinic-1 receptor stimulation on blood pressure regulation. Hypertension 1997; 29: 828–34

    Article  PubMed  CAS  Google Scholar 

  29. Sramko CA, Berger F, Calabrese P, et al. Tolerability and safety of donepezil in the treatment of Alzheimer’s disease: results from a post marketing surveillance study [abstract]. Eur Neuropsychopharmacol 2000; 10Suppl. 3: S368

    Article  Google Scholar 

  30. Feldman H, Gauthier S, Hecker J, et al. A 24-week randomised, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57: 613–20

    Article  PubMed  CAS  Google Scholar 

  31. Mohs R, Doody R, Morris J, et al. A 1-year placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481–8

    Article  PubMed  CAS  Google Scholar 

  32. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomised, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489–95

    Article  PubMed  CAS  Google Scholar 

  33. Dear Healthcare Professional letter [online]. Available from URL: http://www.fda.gov/medwatch/safety/2001/exelon.htm [Accessed 2001 Nov 29]

  34. McKeith I, Del Ser T, Spano PF, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized double-blind, placebo-controlled international study. Lancet 2001; 356: 2031–6

    Article  Google Scholar 

  35. Aarsland D, Larsen JP, Janvin C, et al. Donepezil treatment in Parkinson’s disease with dementia: a double-blind, placebo-controlled crosss-over study [abstract]. Neurology 2001; 56Suppl. 3: A128

    Google Scholar 

  36. Wilkinson DG, Passmore P, Smith R, et al. Comparison of the tolerability, ease of use, and efficacy of donepezil and rivastigmine in Alzheimer’s disease patients: a 12-week multinational study [abstract]. Neurology 2001: 56Suppl. 3: A456–7

    Google Scholar 

Download references

Acknowledgements

The author’s research is funded by the Canadian Institutes for Health Research, the Fonds de la Recherche en Santé du Québec, the National Institute of Aging. Special thanks to Professor Ezio Giacobini for reviewing the manuscript. The author is or has been a consultant to Bayer, Eisai/Pfizer, Janssen-Cilag and Novartis, sponsors of the drugs discussed in this review, but has received no funding for the current work.

Author information

Authors and Affiliations

  1. Alzheimer’s Disease Research Unit, McGill Centre for Studies in Aging, Montreal, Québec, Canada

    Serge Gauthier

Authors
  1. Serge Gauthier
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gauthier, S. Cholinergic Adverse Effects of Cholinesterase Inhibitors in Alzheimer’s Disease. Drugs Aging 18, 853–862 (2001). https://doi.org/10.2165/00002512-200118110-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200118110-00006

Keywords

Search

Navigation